Liran Domachevsky
Papers
1
Total Citations
37
H-Index
1
About
Liran Domachevsky is a leading researcher in nuclear medicine and molecular imaging, with a primary focus on theranostics and targeted radionuclide therapy for prostate cancer. His most impactful work centers on the use of 177Lu-PSMA radioligand therapy in the neoadjuvant setting, as demonstrated by his landmark Phase 1 trial (2022, 37 citations), which evaluated the safety and feasibility of this treatment before radical prostatectomy in high-risk prostate cancer patients. This pioneering study has opened new avenues for integrating radionuclide therapy into multimodal cancer management, potentially improving surgical outcomes and long-term disease control. Domachevsky’s contributions are critical to advancing personalized medicine, where imaging and therapy are combined to target specific tumor biomarkers. His research has been widely cited by the nuclear oncology community, underscoring its translational significance. By bridging the gap between diagnostic imaging and therapeutic intervention, Domachevsky continues to shape the future of precision oncology, offering new hope for patients with aggressive prostate malignancies.
Research Focus
Key Achievements
Top Papers
- 1